An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus

Diabetes/Metabolism Reviews

Volumn 14, Issue 2, 1998, Pages 129-151

  Rabinovitch, Alex ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Autoimmunity; Cytokines; Islet cells

Indexed keywords

CYTOKINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANTIGEN SPECIFICITY; AUTOIMMUNITY; CELL MEDIATED CYTOTOXICITY; CYTOTOXIC T LYMPHOCYTE; GENE DELETION; GENE TARGETING; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0031871335     PISSN: 07424221     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0895(199806)14:2<129::AID-DMR208>3.0.CO;2-V     Document Type: Review

References (170)

1. Bach JF: Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 15: 516-542, 1994.
2. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, and Coffman RL: Two types of murine helper T cell clone. 1. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136: 2348-2357, 1986.
3. Cherwinski HC, Schumacher JH, Brown KD, and Mosmann TR: Two types of mouse helper T cell clone. 3. Further differences in lymphokine synthesis between TH1 and TH2 clones revealed by RNA hybridization, functionally monospecific bioassays and monoclonal antibodies. J Exp Med 166: 1229-1244, 1987.
4. Del Prete GF, De Carli M, Mastromauro C, Biagiotti R, Macchia D, Falagiani P, Ricci M, and Romagnani S: Purified protein derivative (PPD) of Mycobacterium tuberculosis and excretory-secretory antigen(s) (TES) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profiles of cytokine production. J Clin Invest 88: 346-350, 1991.
5. Mosmann TR, and Subash S: The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17: 138-146, 1996.
6. Mosmann TR, and Coffman RL: TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7: 145-173, 1989.
7. Fiorentino DF, Bond MW, and Mosmann TR: Two types of mouse helper T cell. IV. Th2 clones secrete a factor that inhibits cytokine production by ThI clones. J Exp Med 170: 2081-2095, 1989.
8. Chen Y, Kuchroo VK, Inobe J, Hafler DA, and Weiner HL: Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science 265: 1237-1240, 1994.
9. Clerici M, and Shearer GM: The Th1-Th2 hypothesis of HIV infection: New insights. Immunol Today 15: 575-581, 1994.
10. Kolb H: Benign versus destructive insulitis. Diabetes Metab Rev 13: 139-146, 1997.
11. Rabinovitch A: Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM: Therapeutic intervention by immunostimulation? Diabetes 43: 613-621, 1994.
12. + cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 16: 34-38, 1995.
13. Charlton B, and Lafferty KJ: The Th1/Th2 balance in autoimmunity. Curr Opin Immunol 7: 793-798, 1995.
14. Sadelain MWJ, Qin H-Y, Lauzon J, and Singh B: Prevention of type 1 diabetes in NOD mice by adjuvant immunotherapy. Diabetes 39: 583-589, 1990.
15. Sadelain MWJ, Qin H-Y, Sumoski W, Parfrey N, Singh B, and Rabinovitch A: Prevention of diabetes in the BB rat by early immunotherapy using Freund's adjuvant. J Autoimmun 3: 671-680, 1990.
16. Wang T, Singh B, Warnock GL, and Rajotte RV: Prevention of recurrence of IDDM in islettransplanted diabetic NOD mice by adjuvant immunotherapy. Diabetes 41: 114-117, 1992.
17. Shehadeh NN, LaRosa F, and Lafferty KJ: Altered cytokine activity in adjuvant inhibition of autoimmune diabetes. J Autoimmun 6: 291-300, 1993.
18. Campbell IL, Kay TWH, Oxbrow L, and Harrison LC: Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J Clin Invest 87: 739-742, 1991.
19. Rothe H, Faust A, Schade U, Kleemann R, Boose G, Hibino T, Martin S, and Kolb H: Cyclophosphamide treatment of female non-obese diabetic mice causes enhanced expression of inducible nitric oxide synthase and interferon-gamma, but not of interleukin-4. Diabetologia 37: 1154-1158, 1994.
20. Pilstrom B, Bjork L, and Bohme J: Demonstration of a TH1 cytokine profile in the late phase of NOD insulitis. Cytokine 7: 806-814, 1995.
21. Rabinovitch A, Suarez-Pinzon WL, Sorensen O, Bleackley RC, and Power RF: IFN-gamma gene expression in pancreatic islet-infiltrating mononuclear cells correlates with autoimmune diabetes in nonobese diabetic mice. J Immnnol 154: 4874-1882, 1995.
22. Muir A, Peck A, Clare-Salzler M, Song Y-H, Cornelius J, Luchetta R, Krischer J, and Maclaren N: Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-γ transcription. J Clin Invest 95: 628-634, 1995.
23. Hancock WW, Polanski M, Zhang J, Blogg N, and Weiner HL: Suppression of insulitis in nonobese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-β, and prostaglandin-E. Am J Pathol 147: 1193-1199, 1995.
24. Rabinovitch A, Suarez-Pinzon WL, Sorensen O, and Bleackley RC: Inducible nitric oxide synthase (iNOS) in pancreatic islets of nonobese diabetic mice: Identification of iNOS-expressing cells and relationships to cytokines in the islets. Endocrinology 137: 2093-2099, 1996.
25. Zheng XX, Steele AW, Hancock WW, Stevens AC, Nickerson PW, Roy-Chaudhury P, Tian Y, and Strom TB: A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. J Immnnol 158: 4507-4513, 1997.
26. Kolb H, Wörz-Pagenstert U, Kleemann R, Rothe H, Rowsell P, and Scott FW: Cytokine gene expression in the BB rat pancreas: Natural course and impact of bacterial vaccines. Diabetologia 39: 1448-1454, 1996.
27. Zipris D, Greiner DL, Malkani S, Whalen B, Mordes JP, and Rossini AA: Cytokine gene expression in islets and thyroids of BB rats. J Immunol 156: 1315-1321, 1996.
28. Rabinovitch A, Suarez-Pinzon W, El-Sheikh A, Sorensen O, and Power RF: Cytokine gene expression in pancreatic islet-infiltrating leukocytes of BB rats: Expression of Th1 cytokines correlates with beta-cell destructive insulitis and IDDM. Diabetes 45: 749-754, 1996.
29. Chung Y-H, Jun H-S, Kang Y, Hirasawa K, Lee B-R, van Rooijen N, and Yoon J-W: Role of macrophages and macrophage-derived cytokines in the pathogenesis of Kilham rat virus-induced autoimmune diabetes in diabetes-resistant BioBreeding rats. J Immunol 159: 466-471, 1997.
30. Rabinovitch A, Sorensen O, Suarez-Pinzon WL, Power RF, Rajotte RV, and Bleackley RC: Analysis of cytokine mRNA expression in syngeneic islet grafts of NOD mice: Interleukin 2 and interferon gamma mRNA expression correlate with graft rejection and interleukin 10 with graft survival. Diabetologia 37: 833-837, 1994.
31. Suarez-Pinzon W, Rajotte RV, Mosmann TR, and Rabinovitch A: Both CD4+ and CD8+ T-cells in syngeneic islet grafts in NOD mice produce interferon-gamma during beta-cell destruction. Diabetes 45: 1350-1357, 1996.
32. Rothe H, Burkart V, Faust A, and Kolb H: Interleukin-12 gene expression is associated with rapid development of diabetes mellitus in non-obese diabetic mice. Diabetologia 39: 119-122, 1996.
33. Rabinovitch A, Suarez-Pinzon WL, and Sorensen O: Interleukin 12 mRNA expression in islets correlates with β-cell destruction in NOD mice. J Autoimimin 9: 645-651, 1996.
34. Rothe H, Jenkins NA, Copeland NG, and Kolb H: Active stage of autoimmune diabetes is associated with the expression of a novel cytokine, IGIF, which is located near Idd2. J Clin Invest 99: 469-474, 1997.
35. Rothe H, Hibino T, Itoh Y, Kolb H, and Martin S: Systemic production of interferon-gamma inducing factor (IGIF) versus local IFN-γ expression involved in the development of Th1 insulitis in NOD mice. J Autoimmun 10: 251-256, 1997.
36. Fox CJ, and Danska JS: IL-4 expression at the onset of islet inflammation predicts nondestructive insulitis in nonobese diabetic mice. J Immunol 158: 2414-2424, 1997.
37. Arreaza GA, Cameron MJ, Jaramillo A, Gill BM, Hardy D, Laupland KB, Rapoport MJ, Zucker P, Chensue S, Chakrabarti S, Qin HY, Singh B, and Delovitch TL: Neonatal activation of CD28 signaling overcomes T cell anergy and prevents autoimmune diabetes by an IL-4 dependent mechanism. J Clin Invest 100: 2243-2253, 1997.
38. Cetkovic-Cvrlje M, Gerling IC, Muir A, Atkinson MA, Elliott JF, and Leiter EH: Retardation or acceleration of diabetes in NOD/Lt mice mediated by intrathymic administration of candidate β-cell antigens. Diabetes 46: 1975-1982, 1997.
39. Weiner HL: Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today 18: 335-343, 1997.
40. Huang X, Hultgren B, Dybdal N, and Stewart TA: Islet expression of interferon-α precedes diabetes in both the BB rat and streptozotocintreated mice. Immunity 1: 469-478, 1994.
41. Foulis AK, Farquharson MA, and Meager A: Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet ii: 1423-1427, 1987.
42. Huang X, Yuan J, Goddard A, Foulis A, James RFL, Lernmark A, Pujol-Borrell R, Rabinovitch A, Somoza N, and Stewart TA: Interferon expression in the pancreases of patients with type 1 diabetes. Diabetes 44: 658-664, 1995.
43. Somoza N, Vargas F, Roura-Mir C, Vives-Pi M, Fernández-Figueras MT, Ariza A, Gomis R, Bragado R, Martî M, Jaraquemada D, and Pujol-Borrell R: Pancreas in recent onset insulin-dependent diabetes mellitus: Changes in HLA, adhesion molecules and autoantigens, restricted TCR Vβ usage, and cytokine profile. J Immunol 153: 1360-1377, 1994.
44. Foulis AK, McGill M, and Farquharson MA: Insulitis in type 1 (insulin-dependent) diabetes mellitus in man: Macrophages, lymphocytes, and interferon-γ containing cells. J Pathol 165: 97-103, 1991.
45. Mandrup-Poulsen T, Helqvist S, Wogensen LD, Movig J, Pociot F, Johannesen J, and Nerup J: Cytokines and free radicals as effector molecules in the destruction of pancreatic β-cells. Curr Top Microbiol Immunol 164: 169-193, 1990.
46. Rabinovitch A: Roles of cytokines in IDDM pathogenesis and islet β-cell destruction. Diabetes Rev 1: 215-240, 1993.
47. Bolaffi JL, Nowlain RE, Cruz L, and Grodsky GM: Progressive damage of cultured pancreatic islets after single early exposure to streptozotocin. Diabetes 35: 1027-1033, 1986.
48. Pipeleers D, and Van de Winkel M: Pancreatic β cells possess defense mechanisms against cell-specific toxicity. Proc Natl Acad Sci USA: 83: 5267-5271, 1986.
49. Ling Z, In't Veld PA, and Pipeleers DG: Interaction of interleukin-1 with islet β-cells: Distinction between indirect, aspecific cytotoxicity and direct, specific functional suppression. Diabetes 42: 56-65, 1993.
50. Poo W-J, Conrad L, and Janeway CA: Receptor-directed focusing of lymphokine release by helper T cells. Nature 332: 378-380, 1988.
51. Kurt-Jones EA, Beller DI, Mizel SB, and Unanue ER: Identification of a membrane associated interleukin-1 in macrophages. Proc Natl Acad Sci USA 82: 1204-1208, 1985.
52. Kriegler M, Perez C, DeFay K, Albert I, and Lu SD: A novel form of TNF/cachetin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF. Cell 53: 45-53, 1988.
53. Sutton R, Gray DWR, McShane P, Dallman MJ, and Morris PJ: The specificity of rejection and the absence of susceptibility of pancreatic islet β-cells to nonspecific immune destruction in mixed strain islets grafted beneath the renal capsule in the rat. J Exp Med 170: 751-762, 1989.
54. Korsgren O, and Jansson L: Characterization of mixed syngeneic-allogeneic and syngeneic-xenogeneic islet-graft rejections in mice: Evidence of functional impairment of the remaining syn- geneic islets in xenograft rejections. J Clin Invest 93: 1113-1119, 1994.
55. Corbett JA, and McDaniel ML: Intraislet release of IL-1 inhibits β-cell function by inducing β-cell expression of iNOS. J Exp Med 181: 559-568, 1995.
56. Eizirik DL, Flodström M, Karlsen AE, and Welsh N: The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic beta cells. Diabetologia 39: 875-890, 1996.
57. Mandrup-Poulsen T: The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 39: 1005-1029, 1996.
58. McDaniel ML, Kwon G, Hill JR, Marshall CA, and Corbett JA: Cytokines and nitric oxide in islet inflammation and diabetes. Proc Soc Exp Biol Med 211: 24-32, 1996.
59. Rabinovitch A, and Suarez-Pinzon WL: Cytokines and their roles in pancreatic islet β-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol 55: 1139-1149, 1998.
60. Harrison LC, Campbell IL, Colman PG, Chosich N, Kay TWH, Tait BD, Bartholomeusz RK, DeAizpurua HJ, Joseph JL, Chu S, and Kielczynski WE: Type 1 diabetes: Immunopathology and immunotherapy. Adv Endocrinol Metab 1: 35-94, 1990.
61. Kay TWH, Campbell IL, Oxbrow L, and Harrison LC: Over-expression of class I major histocompatibility complex accompanies insulitis in the non-obese diabetic mouse and is prevented by anti-interferon-γ antibody. Diabetologia 34: 779-785, 1991.
62. Hänninen A, Jalkanen S, Salmi M, Toikkanen S, Nikolakaros G, and Simell O: Macrophages, T cell receptor usage, and endothelial cell activation in the pancreas at the onset of insulin-dependent diabetes mellitus. J Clin Invest 90: 1901-1910, 1992.
63. Itoh N, Hanafusa T, Miyazaki A, Miyagawa J-I, Yamagata K, Yamamoto K, Waguri M, Imagawa A, Tamura S, Inada M, Kawata S, Tarui S, Kono N, and Matsuzawa Y: Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest 92: 2313-2322, 1993.
64. Yamada K, Takane-Gyotoku N, Yuan X, Ichikawa F, Inada C, and Nonaka K: Mouse islet lysis mediated by interleukin-1-induced Fas. Diabetologia 39: 1306-1312, 1996.
65. Stassi G, Todaro M, Richiusa P, Giordano M, Mattina A, Sbriglia MS, Lo Monte A, Buscemi G, Galluzzo A, and Giordano C: Expression of apoptosis-inducing CD95 (Fas/Apo-1) on human β-cells sorted by flow-cytometry and cultured in vitro. Transplant Proc 27: 3271-3275, 1995.
66. Giordano C, Stassi G, Todaro M, Richiusa P, De Maria R, Giordano M, Mattina A, Sbriglia MS, and Galluzzo A: Triggering of Fas (Apo-1/CD95)-induced apoptosis in human pancreatic β-cells. Diabetologia 39 (suppl. 1): A10, 1996.
67. Stassi G, De Maria R, Trucco G, Rudert W, Testi R, Galluzzo A, Giordano C, and Trucco M: Nitric oxide primes pancreatic β cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. J Exp Med 186: 1193-1200, 1997.
68. Signore A, Annovazzi A, Procaccini E, Beales. PE, Spencer J, Testi R, and Ruberti G: CD95 and CD95-ligand expression in endocrine pancreas of NOD, NOR and BALB/c mice. Diabetologia 40: 1476-1479, 1997.
69. Suazer-Pinzon W, Sorensen O, Bleackly RC, Ellott JF, Rajotte RV, and Rabinovitch A: β-cell destruction in NOD mice correlates with Fas (CD95) expression on β-cells and proinflammatory cytokine expression in islets. Diabetes (in press).
70. Chervonsky AV, Wang Y, Wong FS, Visintin I, Flavell RA, Janeway CA, and Mattis LA: The role of Fas in autoimmune diabetes. Cell 89: 17-24, 1997.
71. Itoh N, Imagawa A, Hanafusa T, Waguri M, Yamamoto K, Iwahashi H, Moriwaki M, Nakajima H, Miyagawa J, Namba M, Makino S, Nagata S, Kono N, and Matsuzawa Y: Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. J Exp Med 186: 613-618, 1997.
72. Sarvetnick N, Liggitt D, Pitts SL, Hansen SE, and Stewart TA: Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and interferon-gamma. Cell 52: 773-782, 1988.
73. Sarvetnick N, Shizuru J, Liggitt D, Martin L, McIntyre B, Gregory A, Parslow T, and Stewart T: Loss of pancreatic islet tolerance induced by β-cell expression of interferon-γ. Nature 346: 844-847, 1990.
74. Stewart TA, Hultgren B, Huang X, Pitts-Meek S, Hully J, and MacLachlan NJ: Induction of type 1 diabetes by interferon-α in transgenic mice. Science 260: 1942-1946, 1993.
75. Chakrabarti D, Hultgren B, and Stewart TA: IFN-α induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B7.2. J Immunol 157: 522-528, 1996.
76. Allison J, Malcolm L, Chosich N, Morahan G, and Miller JFAP: Inflammation but not autoimmunity occurs in transgenic mice expressing constitutive levels of interleukin-2 in islet β cells. Eur J Immunol 22: 1115-1121, 1992.
77. Allison J, Oxbrow L, and Miller JFA: Consequences of in situ production of IL-2 for islet cell death. Int Immunol 6: 541-549, 1994.
78. Allison J, McClive P, Oxbrow L, Baxter A, Morahan G, and Miller JFAP: Genetic requirements for acceleration of diabetes in non-obese diabetic mice expressing interleukin-2 in islet β-cells. Eur J Immunol 24: 2535-2541, 1994.
79. Higuchi Y, Herrera P, Muniesa P, Huarte J, Belin D, Ohashi P, Aichele P, Orci L, Vassalli J-D, and Vassali P: Expression of a tumour necrosis factor α transgene in murine pancreatic β cells results in severe and permanent insulitis without evolution towards diabetes. J Exp Med 176: 1719-1731, 1992.
80. Picarella DE, Kratz A, Li C, Ruddle NH, and Flavell RA: Transgenic tumor necrosis factor (TNF)-a production in pancreatic islets leads to insulitis, not diabetes: Distinct patterns of inflammation in TNF-α and TNF-β transgenic mice. J Immunol 150: 4136-4150, 1993.
81. Guerder S, Meyerhoff J, and Flavell R: The role of the T cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen. Immunity 1: 155-166, 1994.
82. Grewal IS, Grewal KD, Wong FS, Picarella DE, Janeway CA Jr, and Flavell RA: Local expression of transgene encoded TNF-α in islets prevents autoimmune diabetes in NOD mice by preventing the development of autoreactive islet specific T cells. J Exp Med 184: 1963-1974, 1996.
83. Sarvetnick N: Mechanisms of cytokine-mediated localized immunoprotection. J Exp Med 184: 1597-1600, 1996.
84. McSorley SJ, Soldera S, Malherbe L, Carnaud C, Locksley RM, Flavell RA, and Glaichenhaus N: Immunological tolerance to a pancreatic antigen as a result of local expression of TNFα by islet β cells. Immunity 7: 401-409, 1997.
85. Sallusto F, and Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179: 1109-1118, 1994.
86. Mueller R, Krahl T, and Sarvetnick N: Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 184: 1093-1099, 1996.
87. Mueller R, Bradley LM, Krahl T, and Sarvetnick N: Mechanism underlying counterregulation of autoimmune diabetes by IL-4. Immunity 7: 411-418, 1997.
88. Campbell IL, Hobbs MV, Dockter J, Oldstone MBA, and Allison J: Islet inflammation and hyperplasia induced by the pancreatic islet-specific overexpression of interleukin-6 in transgenic mice. Am J Pathol 145: 157-166, 1994.
89. Di Cosmo BF, Picarella D, and Flavell RA: Local production of human IL-6 promotes insulitis but retards the onset of insulin-dependent diabetes mellitus in non-obese diabetic mice. Int Immunol 6: 1829-1837, 1994.
90. Tilg H, Dinarello CA, and Mier JW: IL-6 and APPs: anti-inflammatory and immunosuppres-sive mediators. Immunol Today 18: 428-432, 1997.
91. + T cells. J Exp Med 185: 461-469, 1997.
92. Wogensen L, Huang X, and Sarvetnick N: Leu-kocyte extravasation into the pancreatic tissue in transgenic mice expressing interleukin 10 in the islets of Langerhans. J Exp Med 178: 175-185, 1993.
93. Moore KV, O'Garra A, de Waal Malefyt R, Vieira P, and Mosmann TR: Interleukin 10. Annu Rev Immunol 11: 165-190, 1993.
94. Wogensen L, Lee M-S, and Sarvetnick N: Production of interleukin 10 by islet cells acceler-ates immune-mediated destruction of β cells in nonobese diabetic mice. J Exp Med 179: 1379-1384, 1994.
95. Moritani M, Yoshimoto K, Tashiro F, Hashimoto C, Miyazaki J-I, Ii S, Kudo E, Iwahana H, Hayashi Y, Sano T, and Itakura M: Transgenic expression of IL-10 in pancreatic islet A cells accelerates autoimmune insulitis and diabetes in non-obese diabetic mice. Int Immunol 6: 1927-1936, 1994.
96. Pennline KJ, Roque-Gaffney E, and Monahan M: Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 71: 169-175, 1994.
97. Sanvito F, Nichols A, Herrera P-L, Huarte J, Wohlwend A, Vassalli J-D, and Orci L: TGF-β1 overexpression in murine pancreas induces chronic pancreatitis and, together with TNF-α, triggers insulin-dependent diabetes. Biochem Biophys Res Commun 217: 1279-1286, 1995.
98. Wilson CA, Jacobs C, Baker P, Baskin DG, Dower S, Lernmark A, Toivola B, Vertrees S, and Wilson D: IL-1β modulation of spontaneous autoimmune diabetes and thyroiditis in the BB rat. J Immunol 144: 3784-3788, 1990.
99. Formby B, Jacobs C, Dubuc P, and Shao T: Exogenous administration of IL-1 alpha inhibits active and adoptive transfer autoimmune diabetes in NOD mice. Autoimmunity 12: 21-27, 1992.
100. Jacob CO, Aiso S, Michie SA, McDevitt HO, and Acha-Orbea H: Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): Similarities between TNF-α and interleukin-1. Proc Natl Acad Sci USA 87: 968-972, 1990.
101. Satoh J, Seino H, Abo T, Tanaka S-I, Shintani S, Ohta S, Tamura K, Sawai T, Nobunaga T, Oteki T, Kumagai K, and Toyota T: Recombinant human tumor necrosis factor-α suppresses autoimmune diabetes in nonobese diabetic mice. J Clin Invest 84: 1345-1348, 1989.
102. Satoh J, Seino H, Shintani S, Tanaka S-I, Ohteki T, Masuda T, Nobunaga T, Oteki T, Kumagai K, and Toyota T: Inhibition of type I diabetes in BB rats with recombinant human tumor necrosis factor-α. J Immunol 145: 1395-1399, 1990.
103. Seino H, Takahashi K, Satoh J, Zhu XP, Sagara M, Masuda T, Nobunaga T, Funahashi I, Kajikawa T, and Toyota T: Prevention of autoimmune diabetes with lymphotoxin in NOD mice. Diabetes 42: 398-404, 1993.
104. Takahashi K, Satoh J, Seino H, Zhu XP, Sagara M, Masuda T, and Toyota T: Prevention of type I diabetes with lymphotoxin in BB rats. Clin Immunol Immunopathol 69: 318-323, 1993.
105. Yang X-D, Tisch R, Singer SM, Cao ZA, Liblau RS, Schreiber RD, and McDevitt HO: Effect of tumor necrosis factor α on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med 180: 995-1004, 1994.
106. Pasparakis M, Alexopoulou L, Episkopou V, and Kollias G: Immune and inflammatory response in TNF alpha-deficient mice: A critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 184: 1397-1411, 1996.
107. Gordon C, and Wofsy D: Effects of recombinant murine tumor necrosis factor-α on immune function. J Immunol 144: 1753-1758, 1990.
108. Rabinovitch A, Suarez-Pinzon WL, Sorensen O, Rajotte RV, and Power RF: TNF-α down-regulates Type 1 cytokines and prolongs survival of syngeneic islet grafts in nonobese diabetic mice. J Immunol 159: 6298-6303, 1997.
109. Gerasimidi A, Sheehan KCF, Schreiber RD, and Lacy PE: Tumor necrosis factor-α prevents rejection of islet xenografts (rat to mouse). Diabetes 42: 651-657, 1993.
110. Serreze DV, Hamaguchi K, and Leiter EH: Immunostimulation circumvents diabetes in NOD/Lt mice. J Antoimmun 2: 759-776, 1989.
111. Zielasek J, Burkart V, Naylor P, Goldstein A, Kiesel K, and Kolb H: Interleukin-2-dependent control of disease development in spontaneously diabetic BB rats. Immunology 69: 209-214, 1990.
112. Rabinovitch A, Suarez-Pinzon WL, Sorensen O, Bleackley RC, Power RF, and Rajotte RV: Combined therapy with interleukin-4 and interleukin-10 inhibits autoimmune diabetes recurrence in syngeneic islet-transplanted nonobese diabetic mice: Analysis of cytokine mRNA expression in the graft. Transplantation 60: 368-374, 1995.
113. Faust A, Rothe H, Schade U, Lampeter EF, and Kolb H: Primary nonfunction of islet grafts in autoimmune diabetic NOD mice is prevented by treatment with IL-4 and IL-10. Transplantation 62: 648-652, 1996.
114. Rapoport MJ, JaramilloA, Zipris D, Lazarus AH, Serreze DV, Leiter DH, Cyopick P, Danska JS, and Delovitch TL: IL-4 reverses T-cell proliferative unresponsiveness and prevents the onset of diabetes in NOD mice. J Exp Med 178: 87-99, 1993.
115. Ewel CH, Sobel DO, Zeligs, BJ, and Bellanti JA: Poly I:C accelerates development of diabetes mellitus in diabetes-prone BB rat. Diabetes 41: 1016-1021, 1992.
116. Scott P: IL-12: Initiation cytokine for cell-mediated immunity. Science 260: 496-497, 1993.
117. Trembleau S, Penna G, Bosi E, Mortara A, Gately MK, and Adorini L: Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J Exp Med 181: 817-821, 1995.
118. O'Hara RM, Henderson SL, and Nagelin AM: Prevention of a ThI disease by a Th1 cytokine: IL-12 and diabetes in NOD mice. Ann NY Acad Sci 795: 241-249, 1996.
119. Campbell IL, Oxbrow L, and Harrison LC: Reduction in insulitis following administration of IFN-gamma and TNF-alpha in the NOD mouse. J Autoimmun 4: 249-262, 1991.
120. Nicoletti F, Zaccone P, Di Marco R, Magro G, Grasso S, Stivala F, Calori G, Mughini L, Meroni PL, and Garotta G: Paradoxical antidiabetogenic effect of γ-interferon in DP-BB rats. Diabetes 47: 32-38, 1998.
121. Serreze D, and Leiter EH: Defective activation of T suppressor cell function in nonobese diabetic mice: Potential relation to cytokine deficiencies. J Immunol 140: 3801-3807, 1988.
122. Lapchak PH, Guilbert LJ, and Rabinovitch A: Tumor necrosis factor production is deficient in diabetes-prone BB rats and can be corrected by complete Freund's adjuvant: A possible immunoregulatory role of tumor necrosis factor in the prevention of diabetes. Clin Immunol Immunopathol 65: 129-134, 1992.
123. Wahl SM, Allen JB, Ohura K, Chenoweth DE, and Hand AR: Interferon-gamma inhibits inflammatory cell recruitment and the evolution of bacterial cell-wall-induced arthritis. J Immunol 146: 95-100, 1991.
124. + T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis. J Clin Invest 95: 2711-2719, 1995.
125. Novelli F, Di Pierro F, di Celle PF, Bertini S, Affaticati P, Garotta G, and Forni G: Environmental signals influencing expression of the IFN-γ receptor on human T cells control whether IFN-γ promotes proliferation or apoptosis. J Immunol 152: 496-504, 1994.
126. Mandrup-Poulsen T, Nerup J, Reimers JI, Pociot F, Andersen HU, Karlsen A, Bjerre U, and Bergholdt R: Cytokines and the endocrine system. I. The immunoendocrine network. Eur J Endocrinol 133: 660-671, 1995.
127. Fowell D, McKnight AJ, Powrie F, Dyke R, and Mason DW: Subsets of CD4+ T-cells and their roles in the induction and prevention of autoimmunity, Immunol Rev 123: 37-64, 1991.
128. + T cell subset that inhibits this autoimmune potential. J Exp Med 177: 627-636, 1993.
129. + cells correlate with cytokine profiles in the spontaneously autoimmune diabetic mouse. Diabetes 45: 71-78, 1996.
130. + Th1 and Th2 T cells derived from the spleens of diabetic NOD mice. J Clin Invest 95: 2979-2985, 1995.
131. Katz JD, Benoist C, and Mathis D: T helper cell subsets in insulin-dependent diabetes. Science 268: 1185-1188, 1995.
132. Pakala SV, Kurrer MO, and Katz JD: T helper 2 (Th2) T cells induce acute pancreatitis and diabetes in immune-compromised nonobese diabetic (NOD) mice. J Exp Med 186: 299-306, 1997.
133. Moritani M, Yoshimoto K, Ii S, Kondo M, Iwahana H, Yamaoka T, Sano T, Nakano N, Kikutani H, and Itakura M: Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1 lymphocytes. J Clin Invest 98: 1851-1859, 1996.
134. + β islet cell-reactive T cell clones that suppress autoimmune diabetes in nonobese diabetic mice. J Exp Med 182: 87-97, 1995.
135. Han H-S, Jun H-S, Utsugi T, and Yoon J-W: A new type of CD4+ suppressor T cell completely prevents spontaneous autoimmune diabetes and recurrent diabetes in syngeneic islet-transplanted NOD mice. J Autoimmun 9: 331-339, 1996.
136. Zekzer D, Wong FS, Wen L, Altieri M, Gurlo T, von Grafenstein H, and Sherwin RS: Inhibition of diabetes by an insulin-reactive CD4 T-cell clone in the nonobese diabetic mouse. Diabetes 46: 1124-1132, 1997.
137. Nicoletti F, Dimarco R, Barcellini W, Magro G, Schorlemmer HU, Kurrle R, Lunetta M, Grasso S, Zaccone P, and Meroni P: Protection from experimental autoimmune diabetes in the non-obese diabetic mouse with soluble interleukin-1 receptor. Eur J Immnnol 24: 1843-1847, 1994.
138. Cailleau C, Diu-Hercend A, Ruuth E, Westwood R, and Carnaud C: Treatment with neutralizing antibodies specific for IL-1β prevents cyclophosphamide-induced diabetes in nonobese diabetic mice. Diabetes 46: 937-940, 1997.
139. Dayer-Metroz MD, Duhamel D, Rufer N, Izui S, Carmichaels D, Wollheim CB, Thompson RC, and Dayer JM: IL-1 receptor antagonist delays spontaneous autoimmune diabetes in BB rats. Eur J Clin Invest 22: A50, 1992.
140. Sandberg J-O, Eizirik DL, and Sandier S: IL-1 receptor antagonist inhibits recurrence of disease after syngeneic pancreatic islet transplantation to spontaneously diabetic non-obese diabetic (NOD) mice. Clin Exp Immimol 108: 314-317, 1997.
141. Debray-Sachs M, Carnaud C, Boitard C, Cohen H, Gresser I, Bedossa P, and Bach JF: Prevention of diabetes in NOD mice treated with antibody to murine IFN-γ. J Autoimmun 4: 237-248, 1991.
142. Nicoletti F, Zaccone P, Di Marco R, Lunetta M, Magro G, Grasso S, Meroni P, and Garotta G: Prevention of spontaneous autoimmune diabetes in diabetes-prone BB rats by prophylactic treatment with antirat interferon-γ antibody. Endocrinology 138: 281-288, 1997.
143. Nicoletti F, Zaccone P, Di Marco R, Di Mauro M, Magro G, Grasso S, Mughini L, Meroni P, and Garotta G: The effects of a nonimmunogenic form of murine soluble interferon-γ receptor on the development of autoimmune diabetes in the NOD mouse. Endocrinology 137: 5567-5575, 1996.
144. Kurschner C, Ozmen L, Garotta G, and Dembic Z: IFN-gamma receptor-Ig fusion proteins: Half-life, immunogenicity and in vivo activity. J Immunol 149: 4096-4100, 1992.
145. Kelley VE, Gaulton GN, Hattori M, Ikegami H, Eisenbarth G, and Strom TB: Interleukin-2 receptor antibody suppresses murine diabetic insulitis and lupus nephritis. J Immunol 140: 59-61, 1988.
146. Pacheco-Silva A, Bastos MG, Muggia RA, Pankewycz O, Nichols J, Murphy JR, Strom TB, and Rubin-Kelley VE: Interleukin-2 receptor targeted fusion toxin (DAB480-IL-2) treatment blocks diabetogenic autoimmunity in non-obese dia-betic mice. Eur J Immunol 22: 697-702, 1992.
147. Hunger RE, Carnaud C, Garcia I, Vassalli P, and Mueller C: Prevention of autoimmune diabetes mellitus in NOD mice by transgenic expression of soluble tumor necrosis factor receptor p55. Eur J Immunol 27: 255-261, 1997.
148. Lee M-S, Mueller R, Wicker LS, Peterson LB, and Sarvetnick N: IL-10 is necessary and sufficient for autoimmune diabetes in conjunction with NOD MHC homozygosity. J Exp Med 183: 2663-2668, 1996.
149. Trembleau S, Penna G, Gregori S, and Adorini L: The role of endogenous IL-12 in the development of spontaneous diabetes in NOD mice. Autoimmunity 21: A087, 1996.
150. Hultgren B, Huang X, Dybdal N, and Stewart TA: Genetic absence of γ-interferon delays but does not prevent diabetes in NOD mice. Diabetes 45: 812-817, 1996.
151. 2. Diabetologia 40: 641-646, 1997.
152. Cavallo MG, Pozzilli P, Bird C, Wadhwa M, Meager A, Visalli N, Gearing AJ, Andreani D, and Thorpe R: Cytokines in sera from insulin-dependent diabetic patients at diagnosis. Clin Exp Immunol 86: 256-259, 1991.
153. Ciampolillo A, Guastamacchia E, Caragiulo L, Lollino G, De Robertis O, Lattanzi V, and Giorgino R: In vitro secretion of interleukin-1 beta and interferon-gamma by peripheral blood lymphomononuclear cells in diabetic patients. Diabetes Res Clin Pract 21: 87-93, 1993.
154. Kallmann BA, Hüther M, Tubes M, Feldkamp J, Bertrams J, Gries FA, Lampeter EF, and Kolb H: Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves' disease. Diabetes 46: 237-243, 1997.
155. Harrison LC, Honeyman MC, DeAizpurua HJ, Schmidli RS, Colman PG, Tait BD, and Cram DS: Inverse relation of humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Lancet 341: 1365-1369, 1993.
156. Yu L, Gianani R, and Eisenbarth GS: Quantitation of glutamic acid decarboxylase autoantibody levels in prospectively evaluated relatives of patients with type I diabetes. Diabetes 43: 1229-1233, 1994.
157. Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GSP, Robinson P, Atkinson MA, Sercarz EE, Tobin AJ, and Lehmann PV: Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 366: 69-72, 1993.
158. Tisch R, Yang X-D, Singer SM, Liblau RS, Fugger L, and McDevitt HO: Immune response to glutamic acid decarboxylase correlates with insulitis in nonobese diabetic mice. Nature 366: 72-75, 1993.
159. Ramiya V, Muir A, and Maclaren N: Insulin prophylaxis in insulin-dependent diabetes mellitus: Immunological rationale and therapeutic use. Clin Immunother 3: 177-183, 1995.
160. Roep BO, Kallan AA, Hazenbos WL, Bruning GJ, Bailyes FM, Arden SD, Hutton JC, and de Vries RR: T-cell reactivity to 38kd insulin-secretory-granule protein in patients with recent-onset type 1 diabetes. Lancet 337: 1439-1441, 1991.
161. Wilson SB, Kent SC, Patton KT, Orban T, Jackson RA, Exley M, Porcelli S, Schatz DA, Atkinson MA, Balk SP, Strominger JL, and Hafler DA: Extreme Th1 bias of regulatory Va24JaQ T cells in type 1 diabetes. Nature 391: 177-181, 1998.
162. Tian J, Atkinson MA, Clare-Salzler MC, Herschenfeld A, Forsthuber T, Lehmann PV, and Kaufman DL: Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 183: 1561-1567, 1996.
163. Ma S-W, Zhao D-L, Yin Z-Q, Mukherjee R, Singh B, Qin H-Y, Stiller CR, and Jevnikar AM: Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance. Nature Med 3: 793-796, 1997.
164. Zhang ZJ, Davidson LE, Eisenbarth G, and Weiner HL: Suppression of diabetes in NOD mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 88: 10252-10256, 1991.
165. + T cells that suppress adoptive transfer of diabetes. J Autoimmun 7: 655-663, 1994.
166. Daniel D, and Wegmann DR: Protection of non-obese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-chain (9-23). Proc Natl Acad Sci USA 93: 956-958, 1996.
167. Polanski M, Melican NS, Zhang J, and Weiner HL: Oral administration of the immunodominant B-chain of insulin reduces diabetes in a cotransfer model of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines. J Autoimmun 10: 339-346, 1997.
168. Ploix C, Bergerot I, Fabien N, Perche S, Moulin V, and Thivolet C: Protection against autoimmune diabetes with oral insulin is associated with the presence of IL-4 type 2 T-cells in the pancreas and pancreatic lymph nodes. Diabetes 47: 39-44, 1998.
169. Harrison LC, Dempsey-Collier M, Kramer DR, and Takahashi K: Aerosol insulin induces regulatory CD8 γδ T cells that prevent murine insulin-dependent diabetes. J Exp Med 184: 2167-2174, 1996.
170. Röcken M, Racke M, and Shevach EM: IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Immunol Today 17: 225-231, 1996.